• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Andrew L. (Larry) Frelinger, PhD

Associate Director of the Center for Platelet Research Studies
Boston Children’s Hospital
300 Longwood Avenue
Karp Research Building - Room 08213
Boston, Massachusetts, United States

Dr. Frelinger is Assistant Professor of Pediatrics at Harvard Medical School and Associate Director of the Center for Platelet Research studies at Boston Children’s Hospital. Dr. Frelinger also holds a joint appointment at the Dana-Farber Cancer Institute. Dr. Frelinger is currently a co-chairman of the Platelet Physiology Scientific Subcommittee of the Scientific and Standardization Committee (SSC), International Society on Thrombosis and Haemostasis (ISTH). He has authored more than 80 peer-reviewed original research articles and has been an invited speaker at national and international meetings on the topic of platelet biology and antiplatelet agents.

For more than 25 years the focus of Dr. Frelinger’s research has been translational studies, combining basic and clinical research, related to platelets and thrombosis. He discovered novel epitopes whose exposure is modulated by ligand binding (ligand-induced binding sites or LIBS) on the cell adhesion receptor glycoprotein IIb-IIIa (GPIIb-IIIa). His work has focused on investigations of basic platelet biology, development of platelet-related therapeutics, and evaluation of anti-platelet therapy through clinical trials.

His research interests include 1) antiplatelet therapy as a treatment modality for sickle cell disease 2) the effects of thrombopoietin mimetics on platelet activation, 3) novel diadenosine tetraphosphate analogs with dual specificity for platelet P2Y1 and P2Y12 ADP receptors for their potential as anti-platelet drugs, 4) platelet function as a contributor to bleeding in immune thrombocytopenia, 5) platelets as models of neurons, and 6) induced pluripotent stem cell-derived platelets for therapeutic applications.


Representative Publications:

The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease

A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation

Platelet activation and inhibition in sickle cell disease (pains) study

A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease

A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity

expertly curated content related to this topic

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.